$11.290
-0.085 (-0.75%)Zum Schluss
TLX im Vergleich zur Peergroup
In the context of the broader market, TLX competes directly with industry leaders such as CRSP and DNTH. With a market capitalization of $3.84B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against CRSP's 100.00% and DNTH's 100.00%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Telix Pharmaceuticals Ltd
Telix reported a revenue of $247 million for Q2 2026, a 21% increase year-over-year, and expects to exceed $1 billion in revenue for the full year 2026, indicating strong growth potential.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.